Trial reportTranslational psychiatry2023
Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial.
Trial report in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- A meta-analysis and systematic review of creativity in schizophrenia: toward an ecological understanding integrating clinical and philosophical perspectives.Frontiers in psychology · 2026Pooled it
- Comparative efficacy of aripiprazole and paliperidone to treatment-as-usual in managing stimulant-induced psychosis: a 24-month randomized controlled trial.Frontiers in pharmacology · 2026Trial
- Cerebellar Functional Alterations During Executive Functioning Are Associated With General Psychopathology in a Cross-Diagnostic Sample.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Article
- Central Obesity-related Brain Alterations Predict Cognitive Impairments in First Episode of Psychosis.Schizophrenia bulletin · 2026Observational
- The role of metabolic health in neurostructural and cognitive alterations in bipolar disorders.Psychological medicine · 2026Article
- Negative association between cognitive functioning and antipsychotic DPsychological medicine · 2026Article
- Comparison of Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Drug-Naïve First-Episode Schizophrenia.Neuropsychiatric disease and treatment · 2026Article
- Neurobehavioral profile of individuals with pathogenic variants in CHD3.European journal of human genetics : EJHG · 2025Article
- Successful antipsychotic dose tapering leading to better cognition in patients with remitted psychosis: Results of Guided Antipsychotic Reduction to Reach Minimum Effective Dose (GARMED) trial.Psychological medicine · 2025Article
- Distinct cognitive trajectories in the early course of psychosis are associated with clinical and functional outcomes longitudinally.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025Article
- Brain Fog and Cognitive Dysfunction in Posttraumatic Stress Disorder: An Evidence-Based Review.Psychology research and behavior management · 2025Review
- Advancing understanding of the mechanisms of antipsychotic-associated cognitive impairment to minimise harm: a call to action.Molecular psychiatry · 2024Article
- Multivariate associations between neuroanatomy and cognition in unmedicated and medicated individuals with schizophrenia.Schizophrenia (Heidelberg, Germany) · 2024Article
- Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.Schizophrenia bulletin · 2024Article
- The Risk for Schizophrenia-Bipolar Spectrum: Does the Apple Fall Close to the Tree? A Narrative Review.International journal of environmental research and public health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 4 countries.
Funding
Abstract
The drivers of cognitive change following first-episode psychosis remain poorly understood. Evidence regarding the role of antipsychotic medication is primarily based on naturalistic studies or clinical trials without a placebo arm, making it difficult to disentangle illness from medication effects. A secondary analysis of a randomised, triple-blind, placebo-controlled trial, where antipsychotic-naive patients with first-episode psychotic disorder were allocated to receive risperidone/paliperidone or matched placebo plus intensive psychosocial therapy for 6 months was conducted. A healthy control group was also recruited. A cognitive battery was administered at baseline and 6 months. Intention-to-treat analysis involved 76 patients (antipsychotic medication group: 37; 18.6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.